Phillip A. Sharp
Co-Founder, Member of the Scientific Advisory BoardDr. Phillip A. Sharp, Ph.D., also known as Phil, has been an Institute Professor of the Center for Cancer Research at Massachusetts Institute of Technology since 1999. He is President of the American Association for the Advancement of Science, Chairman of the Scientific Advisory Board of Fidelity Biosciences, and a Director of the Broad Institute of MIT and Harvard. He is a Co-Founder of Alnylam Pharmaceuticals, Inc., where he has been a Member of the Scientific Advisory Board since May 2025. He is also a Co-Founder of Biogen Inc. and Magen BioSciences, Inc. He is a Scientific Founder of Dewpoint Therapeutics, Inc. and has served as Chair of its Scientific Advisory Board since 2020. He serves as a Member of the Scientific Advisory Board of Danaher Corporation since April 2021 and Skyhawk Therapeutics Inc. since September 2019. He is a Director and Member of the Strategic Advisory Board of Longwood Fund and serves on the Editorial Advisory Board of Xconomy, Inc. Previously, Dr. Sharp was an Independent Director of Vir Biotechnology, Inc. from January 2017 to May 2024. He was an Independent Director and Member of the Scientific Advisory Board at Syros Pharmaceuticals, Inc. from 2012 to September 2022. He was a Director at Alnylam Pharmaceuticals, Inc. from 2002 to May 2025, where he also served as Co-Chairman of the Scientific Strategy and Advisory Group. He was a Director of Biogen Inc. from 1982 to July 2009 and a Director at Biogen MA Inc. since 1982. He also served as a Director and Member of the Scientific Advisory Board at PPD Dermatology, Inc. and as a Director at the McGovern Institute, where he was a Founding Director from 2000 to 2004. He served on the Scientific Advisory Boards of Verastem, Inc. and Sirtris Pharmaceuticals, Inc., and on the Scientific Advisory Committee of the Ludwig Institute for Cancer Research Ltd. At MIT, he served as Director of the Center for Cancer Research from 1985 to 1991 and Head of the Department of Biology from 1991 to 1999. Dr. Sharp's research interests center on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. He received the Nobel Prize for Physiology or Medicine in 1993 for his landmark work on “discontinuous genes” and was a National Medal of Science recipient in 2006. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, and has authored numerous scientific papers. Dr. Sharp received a B.A. from Union College and a Ph.D. in Chemistry from the University of Illinois, Champaign-Urbana in 1969. He did his postdoctoral training at the California Institute of Technology.
Positions
- Company NameAlnylam Pharmaceuticals, Inc.Stock CodeALNYPositionCo-Founder, Member of the Scientific Advisory BoardColleagues
- YLYvonne L. GreenstreetCEO & Director
- AWAmy W. SchulmanIndependent Chair of the Board
- JVJeffrey V. PoultonCFO & Executive VP
- BABryan Andrew SupranChief Legal Officer
- PPPushkal P. GargExecutive VP & Chief Research & Development Officer
- MMMuthiah ManoharanSenior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board
- DEDavid E. I. PyottIndependent Director
